Open AccessCardiac biomarkers and mortality in COVID-19 infection: A review
Author(s) -
Angelica Cersosimo,
Giuliana Cimino,
Ludovica Amore,
Emiliano Calvi,
Greta Pascariello,
Riccardo M. Inciardi,
Carlo Lombardi,
Enrico Vizzardi
Publication year - 2022
Publication title -
monaldi archives for chest disease. pulmonary series/monaldi archives for chest disease/monaldi archives for chest disease. cardiac series
Language(s) - English
Resource type - Journals
eISSN - 2465-101X
pISSN - 1122-0643
DOI - 10.4081/monaldi.2022.2276
Subject(s) - medicine , natriuretic peptide , disease , troponin , covid-19 , cardiology , biomarker , creatine kinase , mortality rate , intensive care medicine , myocardial infarction , heart failure , infectious disease (medical specialty) , biochemistry , chemistry
Lots of meta-analysis emphasize that a great number of hospitalized patients with moderate and severe forms of COVID-19 developed acute myocardial damage, defined as an increase of cardiac biomarkers, such N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), creatine kinase-myocardial band (CK-MB) and of all type of troponins. The highest mortality rate is related with progressively increasing biomarkers levels and with a history of cardiovascular disease. In fact, the biomarkers dosage should be considered as a prognostic marker in all patients with COVID-19 disease at admission, during hospitalization and in the case of clinical deterioration. The purpose of this review is to evaluate cardiovascular prognostic factors in COVID-19 disease throughout the analysis of cardiac biomarkers to early identify the most serious patients and to optimize their outcomes.